| |
 Erika
J. Ernst, Pharm.D.
Associate Professor
S415 Pharmacy Building
Iowa City, IA 52242-1112
(319) 335-8785 telephone
(319) 353-5646 fax
E-mail: erika-ernst@uiowa.edu
| EDUCATION |
|
Added Qualifications in
Infectious Diseases Pharmacotherapy, 1999-2005. |
|
Board Certification in Pharmacotherapy,
1998-2005. |
|
Infectious Diseases Fellowship,
University of California, San Francisco, School of Pharmacy,
San Francisco, California, 1993-1995. |
|
Pharmacy Practice Residency,
University of Southern California, School of Pharmacy,
Los Angeles, California, 1992-1993. |
|
Doctor of Pharmacy, University
of Southern California, School of Pharmacy, Los Angeles,
California, 1988-1992. |
|
Prepharmacy Courses, Palomar Community College, 1985-1988. |
| Professional
Experience |
|
Associate Professor, The University of
Iowa, College of Pharmacy, Iowa City, Iowa, 2002-present. |
|
Assistant Professor, The University of
Iowa, College of Pharmacy, Iowa City, Iowa, 1998-2002. |
|
Associate, The University of Iowa, College
of Pharmacy, Iowa City, Iowa, 1995-1998. |
| Honors
and Awards |
|
Who’s Who in America,
56th edition, 2002. |
|
Hoechst-Roussel Excellence
in Clinical Pharmacy Award, 1992. |
|
Phi Lambda Sigma Pharmacy
Leadership Fraternity, 1991. |
|
Rho Chi Society, 1991. |
|
| Organizational
Memberships |
|
Johnson County Pharmacists
Association |
|
American Society for Microbiology,
1996-present. |
|
Society of Infectious Diseases
Pharmacists, 1995-present; Awards Committee member, 2000-01, Awards Committee Vice-Chair, 2001-2002, Committee to evaluate credentialing, 2006-2007. |
|
American Association of
Colleges of Pharmacy, 1995-present. |
|
American Society of Health-systems
Pharmacists, 1995-present. |
|
American College of Clinical
Pharmacy, 1992-present; Membership Committee member, 1998-1999, 1999-2000, Infectious Diseases PRN initiatives committee member 1998-1999, Infectious Diseases PRN awards committee member 1999-2000, 2000-2001, Infectious Diseases PRN minisabattical committee member 2006-2007, Infectious Diseases PRN president-elect 2006-2007. |
|
Lambda Kappa Sigma Pharmacy
Fraternity |
| Select
Scholarly Activities |
|
Zillich AJ, Sutherland JM, Wilson SJ, Diekema DJ, Ernst EJ, Vaughn TE, Doebbeling BN. Antimicrobial Use Control Measures to Prevent and Control Antimicrobial Resistance in US Hospitals. Infection Control and Hospital Epidemiology 2006;27:1088-1095. |
|
Ernst EJ, Raley G, Herwaldt LA, Diekema DJ. The Importance of Control Group Selection for Evaluating Antimicrobial Usage as a Risk Factor for Methicillin-resistant Staphylococcus aureus Bacteremia. Infection Control and Hospital Epidemiology 2005;52:634-637. |
|
Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health and Quality of Life Outcomes 2005; 3:45 (27 July 2005). |
|
Flach SD, Diekema DJ, Yankey JW, BootsMiller BJ, Vaughn TE, Ernst EJ, Ward MM, Doebbeling BN. Variation in the use of procedures to monitor antimicrobial resistance in US hospitals. Infection Control and Hospital Epidemiology 2005;26:31-38. |
|
Ernst EJ,
Diekema DJ, BootsMiller BJ, Vaughn TE, Yankey JW, Flach
SD, Ward MM, Franciscus C, Acosta E, Pfaller MA, Doebbeling
BN. Are US Hospitals Following National Guidelines for
the Analysis and Presentation of Cumulative Antimicrobial
Susceptibility Data? Diagonstic Microbiology and Infectious
Diseases 2004;49:141-145. |
|
Flach SD, Diekema DJ, Yankey
JW, BootsMiller BJ, Vaughn TE, Ernst EJ, Ward MM, Doebbeling BN. Variation in the use of procedures
to detect and report antimicrobial resistance in US hospitals.
Infection Control and Hospital Epidemiology (in press). |
|
Diekema, DJ, BootsMiller
B, Vaughn T, Woolson R, Yankey J, Ernst EJ,
Flach S, Ward M, Franciscus C, Pfaller MA, Doebbeling
BN. Antimicrobial Resistance Trends and Outbreak Frequency
in United States Hospitals. Clinical Infectious Diseases
2004;38:78-85. |
|
Keele DS, Crank CW, Ernst
EJ, Klepser ME. Evaluation of Amphotericin B
and Voriconazole in Combination against Fluconazole Susceptible
and Resistant Candida Isolates using Time-Kill
Methodology. Journal of Infectious Disease Pharmacotherapy
2003;6(1) 49-63. |
|
Hoffman HL, Klepser ME, Ernst
EJ, Petzold CR, Saadah LM, Doern GV. Influence
of Macrolide Susceptibility on Efficacies of Clarithromycin
and Azithromycin against Streptococcus pneumoniae in a
Murine Lung Infection Model. Antimicrobial Agents and
Chemotherapy 2003;47:739-46. |
|
Klepser ME, Klepser DG, Ernst EJ, Brooks J, Diekema DJ, Mozaffari
E, Hendrickson J, Doern GV. Health Care resource utilization
associated with treatment of Penicillin-susceptiible and
-Nonsusceptible isolates of Streptococcus pneumoniae.
Pharmacotherapy 2003;23:349-359. |
|
Huffman A, Klepser ME, Ernst
EJ, Keele D, Roling E, Viljoen AM. Susceptibility
of opportunistic bacteria and yeasts to the volatile oils
of Artemisia afra, Lippia Javanica, Lippa scrabberrima,
Myrothamnus flabellifolius and Osmitopsis asteriscoides.
Journal of Infectious Diseases Pharmacotherapy 2002;5(4):43-50. |
|
Viljoen AM, Klepser ME, Ernst EJ, Keele D, Roling E, van Vuuren
S, Demirci B, Baúer KHC, van Wyk B-E. The composition
and antimicrobial activity of the essential oil of the
resurrection plant Myrothamnus flabellifolius. South African
Journal of Botany 2002;68(1)661-666. |
|
Klepser, ME, Lewis RE, Ernst
EJ, Petzold CR, Bailey EM, Burgess DS, Carver
PL, Lacy MK, Mercier RC, Nicolau DP, Zhanel GG, Pfaller
MA. Multi-center evaluation of antifungal time-kill methods.
Journal of Infectious Diseases Pharmacotherapy 2001;5(2)29-41). |
|
Ernst EJ , Petzold CR, Keele DJ, Roling EE, Klepser ME. Evaluation
of the in vitro activity of Micafungin (FK-463) against
Candida spp. using microdilution, time-kill, and post-antifungal
effect studies. Antimicrobial Agents and Chemotherapy
2002;46:3846-3853. |
|
Keele DJ, DeLallo VC, Lewis
RE, Ernst EJ, Klepser ME. Evaluation
of amphotericin b and flucytosine in combination against
Candida albicans and Cryptococcus neoformans using time-kill
methododolgy. Diagnostic Microbiology and Infectious Diseases
2001;41:121-126. |
|
Ernst EJ , Yodoi K, Roling EE, Klepser ME. Rate and extent of antifungal
activity of amphotericin b, flucytosine, fluconazole and
voriconazole against Candida lusitaniae determined
by microdilution, Etest and time-kill methods. Antimicrobial
Agents and Chemotherapy 2002;46:578-581. |
|
Roling EE, Klepser ME, Wasson
A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal
activities of fluconazole, caspofungin (MK0991), and Anidulafungin
(LY303366) alone and in combination against Candida spp
and Cryptococcus neorformans via time-kill methods. Diagnostic
Microbiology and Infectious Diseases 2002;43:13-17. |
|
Hoffman HL, Ernst
EJ, Redford TW, Klepser MK. Effect of CpG DNA
oligodeoxynucleotides and echinacea on the fungicidal
activity of amphotericin B in a disseminated murine candidal
infection model. Journal of Infectious Diseases Pharmacotherapy
2001;4:55-66. |
|
Ernst EJ , Klepser ME, Petzold CR, Doern GV. Evaluation of survival
and pharmacodynamic relationships for five fluoroquinolones
in a pneumococcal lung infection model. Pharmacotherapy
2002;22:463-470. |
|
Klepser ME, Ernst
EJ, Petzold CR, Rhomberg P, Doern GV. Comparative
bactericidal activities of ciprofloxacin, clinafloxacin,
grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin
assessed in a dynamic in vitro model against Streptococcus
pneumoniae. Antimicrobial Agents and Chemotherapy 2001;45:673-678. |
|
Hoffman HL, Lewis RE, Klepser
ME, Ernst EJ, Pfaller MA. Influence of
fluconazole susceptibility on in vitro expression of fluconazole
induced antagonism of the fungicidal activity of amphotericin
b in Candida albicans and Cryptococus neoformans. Diagnostic
Microbiology and Infectious Diseases (submitted). |
|
Ernst EJ, Klepser ME, Klepser
TB, Nightingale CH, Hunsicker LG. Comparison of the serum
and intracellular pharmacokinetics of azithromycin in
healthy and diabetic volunteers. Pharmacotherapy 2000;20:657-661. |
|
Gunderson SM, Hoffman H,
Ernst EJ, Pfaller MA, Klepser ME In vitro pharmacodynamic
characteristics of Nystatin including time-kill and post
antifungal effect. Antimicrobial Agents and Chemotherapy
(accepted). |
|
Klepser ME, Malone D, Lewis
RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamic
characteristics using time-kill methodology. Antimicrobial
Agents and Chemotherapy. 2000;44:1917-1920. |
|
Lewis RE, Klepser ME, Ernst
EJ, Snabes MA, Jones RN. Comparison of oral immediate-release
and extended-release metronidazole bactericidal activity
against Bacteroides spp. using and in vitro model of infection.
Diagnostic Microbiology and Infectious Disease. 2000;37:51-55. |
|
Ernst EJ, Klepser ME, Pfaller
MA. Post-antifungal effect of echinocandin, azole and
polyene antifungal agents against Candida albicans and
Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy.
2000;44:1108-1111. |
|
| Related
links |
|
Society
of Infectious Disease Pharmacists |
|
American
College of Clinical Pharmacy |
|
American
Society for Microbiology |
|
|
|
| |
|
|
| |
|
|
|
